An interventional study of iStent inject surgery in Primary Open Angle Glaucoma (POAG), sponsored by Glaukos Corporation. Terminated at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-09.
Sponsored by Glaukos Corporation · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications. Outcomes will be evaluated at 12 and 24 months.
Exclusion Criteria:
Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
Device: iStent inject surgery
Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
IOP reduction at 12 and 24 months on same number or fewer medications
IOP reduction at 12 and 24 months on same number or fewer medications
Time frame: 12 months and 24 months
This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glaukos Corporation